Caribou Biosciences, Inc. CRBU

US Biotechnology

$0.40 ▼ -5.88% ($-0.02)

🧊 52W Low ⬇️ Below Yest. Low 🎢 High Beta

Open $0.41

Prev Close $0.42

Day Range $0.39 – $0.43

52W Range $0.40 – $2.49

Market Cap $45.35M

Beta 2.62

EPS (TTM) $-1.08

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2021-07-23
Shares Out.	107,210,000
Website	cariboubio.com ↗
Phone	15109826030
Employees	97
Revenue	$1.6M
Gross Profit	$1.6M
Net Income	-$26.6M
Free Cash Flow	-$93.2M
Total Assets	$123.0M
Total Liabilities	$46.4M
Equity	$76.6M

About Caribou Biosciences, Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

Caribou Biosciences, Inc. is a publicly traded company under the ticker symbol CRBU on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.